Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A well differentiated, intermediate grade tumor with neuroendocrine differentiation that arises from the stomach. The mitotic count is 2-20 per 10 HPF and/or the Ki67 index is 3 to 20 percent.
Biomarker and diagnostic research for gastric neuroendocrine tumor G2 has been reported in the published literature.
No clinical trials have been registered for gastric neuroendocrine tumor G2.
47 publications have been identified in PubMed for gastric neuroendocrine tumor G2. Research spans Clinical Trial Publication (28%), Case Report / Case Series (21%), and Diagnostic / Biomarker (19%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 13 | 28% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 11:30 AM UTC
Patient case studies
10 |
21% |
Testing and diagnosis research | 9 | 19% |
Disease patterns and progression | 6 | 13% |
Laboratory research | 5 | 11% |
Research summaries | 3 | 6% |
New treatment approaches | 1 | 2% |
Asmar C (2026). [PMID: 41547118](https://pubmed.ncbi.nlm.nih.gov/41547118/). *Cancer epidemiology*. [Clinical Trial Publication]
Ohashi T (2026). [PMID: 41697540](https://pubmed.ncbi.nlm.nih.gov/41697540/). *Clinical journal of gastroenterology*. [Epidemiology / Natural History]
Skill NJ (2026). [PMID: 41499067](https://pubmed.ncbi.nlm.nih.gov/41499067/). *Journal of gastrointestinal cancer*. [Diagnostic / Biomarker]
Uccella S (2026). [PMID: 41273419](https://pubmed.ncbi.nlm.nih.gov/41273419/). *Virchows Archiv : an international journal of pathology*. [Review / Meta-Analysis]
Ergenç M (2026). [PMID: 41998800](https://pubmed.ncbi.nlm.nih.gov/41998800/). *Cancer Control*. [Diagnostic / Biomarker]
Vyas M (2026). [PMID: 41717808](https://pubmed.ncbi.nlm.nih.gov/41717808/). *The American journal of surgical pathology*. [Basic Science / Preclinical]
Maly M (2025). [PMID: 39604221](https://pubmed.ncbi.nlm.nih.gov/39604221/). *Journal of neuroendocrinology*. [Diagnostic / Biomarker]
Micsik T (2025). [PMID: 41574207](https://pubmed.ncbi.nlm.nih.gov/41574207/). *Pathology oncology research : POR*. [Clinical Trial Publication]
Kiesewetter B (2025). [PMID: 39316250](https://pubmed.ncbi.nlm.nih.gov/39316250/). *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico*. [Clinical Trial Publication]
Kasai Y (2025). [PMID: 39547997](https://pubmed.ncbi.nlm.nih.gov/39547997/). *Journal of gastroenterology*. [Case Report / Case Series]
AI-curated news mentioning gastric neuroendocrine tumor G2
Updated Mar 7, 2026
A recent study evaluates surgical paradigms for gastric neuroendocrine tumors, comparing outcomes with adenocarcinoma approaches. This analysis provides insights into treatment strategies for this rare tumor type.
A case study highlights a gastric neuroendocrine tumor exhibiting a unique raspberry-like appearance, potentially linked to acid-suppressive therapy-related gastropathy. This finding may provide insights into the pathology of gastric tumors in patients undergoing long-term acid suppression.